Oncosec tech to deliver genetically engineered proteins directly into tumours

By Flora Southey contact

- Last updated on GMT


Related tags: Dna, Medicine

Avacta says a research collaboration using Oncosec’s gene delivery technology could lead to the development of gene delivered Affimer immunotherapies.

The partnership teams Avacta’s Affimer protein platform – based on a small human protein that can be engineered to bind with high specificity and affinity to a wide range of protein targets – with Oncosec’s ImmunoPulse technology, to deliver DNA encoded proteins directly into animal model tumours.

DNA encoded immune-modulatory Affimers investigated in the collaboration include Avacta’s PD-L1 inhibitor (AVA04).

The collaboration “will show how well the Oncosec Immunopulse and Avacta Affimer technology work together to deliver clinical relevant dosing levels and efficacy of the PD-L1 blockade in an animal model,” ​said Avacta CEO Alistair Smith.

“Both companies will also potentially benefit in the future from the development of an Affimer therapeutic candidate delivered using the Oncosec technology through a licensing model,” ​he told us.

The programme is designed to generate proof of concept data, to create immunotherapy combinations for clinical development and/or licensing.

“If these data are good then there is the potential to partner with larger pharmaceutical companies who are interested in gene delivery of small therapeutic proteins most likely in oncology,” ​said Smith.

The deal marks Avacta’s third collaboration for Affimer gene therapies, with Moderna Therapeutics and FIT Biotech also using the platform.

Earlier this month, Avacta signed a licensing deal​ to develop drug conjugates using with Glythera. 

Related topics: Drug Delivery, Delivery technologies

Related news

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Local lab Data Management

Local lab Data Management

Q² Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...